Jianyao Wang

机构：Johnson & Johnson (United States), Janssen (Belgium), Queen Mary University of London, Tianjin Medical University General Hospital, Zhengzhou University, Janssen (United States), Shenzhen Children's Hospital · ORCID：0000-0003-2559-8849

发表论文 110 篇 · 总被引 2839 次 · h-index 31

代表论文

• Plant-derived exosomal nanoparticles: potential therapeutic for inflammatory bowel disease (2023 · Nanoscale Advances · 被引 66)
• Exosomal LINC00460/miR-503-5p/ANLN positive feedback loop aggravates pancreatic cancer progression through regulating T cell–mediated cytotoxicity and PD-1 checkpoint (2022 · Cancer Cell International · 被引 31)
• Hypoxia-regulated secretion of IL-12 enhances antitumor activity and safety of CD19 CAR-T cells in the treatment of DLBCL (2023 · Molecular Therapy — Oncolytics · 被引 24)
• Emodin Inhibits NLRP3 Inflammasome Activation and Protects Against Sepsis via Promoting FUNDC1-Mediated Mitophagy (2025 · International Journal of Biological Sciences · 被引 22)
• Translational Pharmacokinetics of Icotrokinra, a Targeted Oral Peptide that Selectively Blocks Interleukin-23 Receptor and Inhibits Signaling (2025 · Dermatology and Therapy · 被引 14)
• A novel microenvironment regulated system CAR-T (MRS.CAR-T) for immunotherapeutic treatment of esophageal squamous carcinoma (2023 · Cancer Letters · 被引 14)